Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06576115 · ClinicalTrials.gov registry record · Phase 2
Gemcitabine, Nab-paclitaxel Plus the TheraBionic P1 (an Amplitude-Modulated Radiofrequency Electromagnetic Fields) Device to Treat Metastatic Pancreatic Cancer
A Phase 2 study of Metastatic Pancreatic Adenocarcinoma, sponsored by Barbara Ann Karmanos Cancer Institute.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 7
- Study locations
NCT06576115 is a Phase 2 study of Metastatic Pancreatic Adenocarcinoma that is actively recruiting participants, run by Barbara Ann Karmanos Cancer Institute. The registered enrollment target is 30 participants, below the 89-participant average among 37 other Metastatic Pancreatic Adenocarcinoma trials with a reported enrollment target (66% lower). The trial reports 7 study locations across 1 state.
The verdict
NCT06576115, a Phase 2 study of Metastatic Pancreatic Adenocarcinoma, is actively recruiting participants, sponsored by Barbara Ann Karmanos Cancer Institute.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 7
- Study locations
Study Summary
The goal of this study is to learn if the combination of nab-paclitaxel, gemcitabine and an Amplitude-Modulated Radiofrequency Electromagnetic Fields device (Therabionic P1) is safe and effective for patients with adenocarcinoma of the pancreas.
Conditions Studied
Interventions
- DRUG Gemcitabine
- DRUG Nab paclitaxel
- DEVICE TheraBionic P1
Study Locations (7)
Michigan
- Karmanos Cancer Institute at McLaren Clarkston - Clarkston
- Karmanos Cancer Institute - Detroit
- Karmanos Cancer Institute at McLaren Flint - Flint
- Karmanos Cancer Institute at McLaren Greater Lansing - Lansing
- Karmanos Cancer Institute at McLaren Lapeer Region - Lapeer
- Karmanos Cancer Institute at McLaren Northern Michigan, Petoskey - Petoskey
- Karmanos Cancer Institute at McLaren Port Huron - Port Huron
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2025-02-28 |
| Est. Completion | 2027-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06576115
The ClinicalTrials.gov registry entry for NCT06576115 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 89-participant average among 37 other Metastatic Pancreatic Adenocarcinoma trials with a reported enrollment target (66% lower). The listed sponsor is Barbara Ann Karmanos Cancer Institute, which has 139 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Metastatic Pancreatic Adenocarcinoma appearing as the primary indexed condition, and to 3 interventions - of which Gemcitabine is the first listed.
NCT06576115 reports 7 study locations spanning 1 distinct geographic area - top geographies include Michigan.
Frequently Asked Questions
What is clinical trial NCT06576115 about?
NCT06576115 is a clinical study titled "Gemcitabine, Nab-paclitaxel Plus the TheraBionic P1 (an Amplitude-Modulated Radiofrequency Electromagnetic Fields) Device to Treat Metastatic Pancreatic Cancer". The goal of this study is to learn if the combination of nab-paclitaxel, gemcitabine and an Amplitude-Modulated Radiofrequency Electromagnetic Fields device (Therabionic P1) is safe and effective for patients with adenocarcinoma of the pancreas.
What is the current status of trial NCT06576115?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2025-02-28. Estimated completion is 2027-07.
What conditions does trial NCT06576115 study?
This clinical trial studies the following conditions: Metastatic Pancreatic Adenocarcinoma.
What interventions are being tested in trial NCT06576115?
The interventions under investigation include: Gemcitabine (DRUG), Nab paclitaxel (DRUG), TheraBionic P1 (DEVICE).
Who is sponsoring clinical trial NCT06576115?
This trial is sponsored by Barbara Ann Karmanos Cancer Institute, which has 139 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06576115 being conducted?
This trial has 7 study locations across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Pancreatic Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Photoradiation With Verteporfin to Facilitate Immunologic Activity of Pembrolizumab in Unresectable, Locally Advanced or Metastatic Pancreatic Cancer
RECRUITING · Phase 2
-
Evaluating NALIRIFOX vs Modified Gemcitabine, Nab-Paclitaxel and Cisplatin in Patients With Locally Advanced and Metastatic Pancreatic Adenocarcinoma
RECRUITING · Phase 2
-
BMS-986340 in Combination With Nivolumab, Gemcitabine and Nab-paclitaxel for the Treatment of Metastatic and Recurrent Pancreatic Adenocarcinoma
RECRUITING · Phase 2
-
Biologically Optimized Infusion Schedule of Gemcitabine and Nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer
RECRUITING · Phase 2
-
Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
ACTIVE NOT RECRUITING · Phase 2
-
FOLFIRI or Modified FOLFIRI and Veliparib as Second Line Therapy in Treating Patients With Metastatic Pancreatic Cancer
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.